CRD733 (ASP4901) is a potent, selective cGMP-specific PDE9 (phosphodiesterase 9) inhibitor.

Gemlapodect (NOE-105) is a potent, selective PDE10A inhibitor with a potential therapeutic effect for the treatment of COFD.

MCI-030 (ADT 061) is a potent, selective PDE10 inhibitor, inhibits recombinant PDE10 using cGMP as a substrate with IC50 of 0.3 uM.

ME3183 is a potent, selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 2.33, 1.28 and 1.63 nM for PDE4B1, PDE4A1A and PDE4D2 respectively.

A potent and selective PDE10A inhibitor with IC50 of 0.37 nM.

TOP-N53 is a dual-acting nitric oxide (NO) donor and selective PDE5 inhibitor, potently inhibits PDE5 with IC50 of 1.6 nM.

TPN171 (TPN-171) is a highly potent, selective phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 0.62 nM, 32-fold selectivity over PDE6.

Yonkenafil is a potent, selective PDE5 inhibitor with IC50 of 2.0 nM.

ABD298 is a potent, selective ABHD13 inhibitor, inhibits HEK293T cells expressing recombinant mouse ABHD13 with IC50 of 0.98 uM.

KT-203 (KT203) is a potent, selective inhibitor of α/β-hydrolase domain 6 (ABHD6) with IC50 of 3.9 nM in 2-AG hydrolysis assays.

VU533 is a small molecule activator of N-acyl-phosphatidylethanolamine hydrolyzing phospholipase D (NAPE-PLD) with EC50 of 0.3 uM, enhances efferocytosis by macrophages.

VU534 is a small molecule activator of N-acyl-phosphatidylethanolamine hydrolyzing phospholipase D (NAPE-PLD) with EC50 of 0.3 uM, enhances efferocytosis by macrophages.

IPR3011 is a small-molecule uPAR-uPA protein-protein interaction inhibitor with Ki of 2.4 uM.

WX-293 is a highly selective small-molecule inhibitor of urokinase-type plasminogen activator (uPA) with Ki of 2.4 uM.

WX-340 is a highly specific and selective, peptidic cyclic competitive inhibitor of urokinase-type plasminogen activator (uPA) with Ki of 12 and 170 nM for human and mouse uPA, respectively, inhibit 10 Units of human uPA with IC50 of 90 nM.

GSK-199 is a potent, highly selective and reversible protein arginine deiminase PAD4 inhibitor with IC50 of 250 nM in FP binding assay (0.2 mM Ca), 200 nM in PAD4 NH3 release inhibition assay.

JBI-589 (JBI589) is potent, selective, orally active PAD4 small molecule inhibitor, reduces CXCR2 expression and blocks neutrophil chemotaxis.

ML325 (ML 325) is a potent, irreversible pan-protein arginine deiminase (PAD) inhibitor with IC50 of 70 nM, 200 nM 170 nM, and 240 nM for PAD1, 2, 3, and 4 in vitro respectively.

ATUX-1215 is a direct, orally active small molecule activator of protein phosphatase 2A (PP2A), suppresses bleomycin-induced fibrosis in vivo.

ATUX-792 is a small molecule activator of protein phosphatase 2A (PP2A), decreases survival, proliferation, and motility of neuroblastoma in vitro and tumor growth in vivo.

CNBCA is a selective, competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 (SHP2) with IC50 of 0.87 uM, effectively suppresses breast cancer cell phenotypes.

DS-1211 (DS1211) is a potent, selecitve inhibitor of tissue-nonspecific alkaline phosphatase (TNAP) with IC50 of 3.4 nM.